Figure 1 Kaplan-meier Plot Of Time To First Adjudication Committee-determined Nmosd Relapse In The Randomized-controlled Period (itt Population; Anti-aqp4 Antibody Positive Patients) (Inebilizumab Injection 100 mg Per 10 mL 01)
Uplizna Injection
Product Images NDC 75987-150
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Uplizna (NDC 75987-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Horizon Therapeutics Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel (100 mg/10 mL Vial Carton)
UPLIZNA is an injection medication used for intravenous infusion. Before use, the product must be diluted and prepared into three single-dose vials or complete doses of 300 mg. Any unused portion should be discarded. Each patient should be given a copy of the accompanying injection medication guide. The dosage information is available in the prescribing information. The store should keep the vials upright. The text also mentions the manufacturer, UPC code, and NDC number but no information that can be helpful.*
Principal Display Panel (100 mg/10 mL Vial Label)
UPLIZNA is an injection used for intravenous infusion after dilution. The medication contains 100mg/mL (10mg/m). Its active ingredient is inehilizumab-cdon. The product is distributed in an APL2220/2 - 250LBLOT and its NDC is 75987-150-01. No additional information is available from the provided text.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
